Last reviewed · How we verify
neoadjuvant chemotherapy plus concurrent chemoradiotherapy
This treatment involves the use of chemotherapy and radiation therapy to target and kill cancer cells.
This treatment involves the use of chemotherapy and radiation therapy to target and kill cancer cells. Used for Locally advanced non-small cell lung cancer, Locally advanced esophageal cancer.
At a glance
| Generic name | neoadjuvant chemotherapy plus concurrent chemoradiotherapy |
|---|---|
| Also known as | Neoadjuvant Chemotherapy Followed by CCRT |
| Sponsor | Sun Yat-sen University |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Neoadjuvant chemotherapy is administered before the main treatment to reduce the size of the tumor, while concurrent chemoradiotherapy involves the simultaneous use of chemotherapy and radiation therapy to further target and kill cancer cells.
Approved indications
- Locally advanced non-small cell lung cancer
- Locally advanced esophageal cancer
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Fatigue
- Hair loss
Key clinical trials
- Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) (PHASE2)
- Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC (PHASE2)
- Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma (PHASE2)
- Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC (PHASE3)
- Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer (PHASE3)
- Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC (PHASE2)
- A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy (PHASE2)
- Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: